ATS 2020 Advance Program

Objectives At the conclusion of this session, the participant will be able to: • explore the role of novel imaging techniques in assessing ventilation and air flow; • understand the emerging utility of multimodal imaging to delineate perfusion abnormalities in pulmonary disease; • understand which methods are emerging versus ready for clinical use. Quantitative methods using imaging to gain insight into pulmonary physiology are increasingly becoming available to clinicians and researchers. In this symposium, we review a range of novel imaging methods that enhance our understanding of pulmonary physiology in health and disease, including quantification of ventilation, detailed perfusion and cardiopulmonary blood flow. Attendees will learn about the latest clinically available techniques as well as emerging methods that show promise. Chairing: G.K. Prisk, PhD, DSc, La Jolla, CA P. Kohli, MD, Boston, MA F.N. Rahaghi, MD, PhD, Boston, MA 2:15 The Power of PET Imaging: Physiologic Insight into Regional Ventilation T. Winkler, PhD, Boston, MA 2:35 Functional Respiratory Imaging and Aerosols Deposition J. De Backer, MSc, PhD, Kontich, Belgium 2:55 Quantifying Perfusion Using DECT: Where Do We Stand? E.A. Hoffman, PhD, ATSF, Iowa City, IA 3:15 Out of the Gate: What Can Intracardiac Flow Visualizations Tell us About Cardiopulmonary Interactions? M. Schafer, MS, Denver, CO 3:35 Matching Blood and Air: Where Do We Stand? S.R. Hopkins, MD, PhD, La Jolla, CA 3:55 Putting It All Together: Integrating Imaging Data into Quantitative Models M.H. Tawhai, PhD, Auckland, New Zealand TRANSLATIONAL SCIENTIFIC SYMPOSIUM C90 MODULATING TYPE 2 AIRWAY INFLAMMATION: THINKING OUTSIDE OF IL-4, IL-5, AND IL-13 Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology 2:15 p.m. - 4:15 p.m. Target Audience Health care providers and basic scientists interested in learning more about novel immunological targets for asthma that are still in early development/clinical trials. Objectives At the conclusion of this session, the participant will be able to: • understand the importance of type 2 inflammation in a particular subset of severe persistent asthma; • identify mediators that contribute to type-2 inflammation apart from IL-4, IL-5, and IL-13; • learn the results of recent clinical trials in severe asthma focusing on novel targets of type-2 inflammation. The session will discuss new targets of type 2 airway inflammation currently being studied for the treatment of asthma- thinking outside of IL-4, IL-5, and IL-13. Chairing: W. Stevens, MD, PhD, Chicago, IL G.M. Gauvreau, PhD, ATSF, Hamilton, Canada 2:15 Targeting TSLP P. O'Byrne, MD, Hamilton, Canada 2:35 Targeting IL-33 I.D. Pavord, MD, Oxford, United Kingdom 2:55 Targeting the Prostaglandin D2 Receptor C.E. Brightling, BSc(Hons), MBBS, PhD, Leicester, United Kingdom 3:15 Targeting JAK/STAT Pathways M. Gadina, PhD, Bethesda, MD 3:35 Targeting Tyrosine Kinases E. Israel, MD, Boston, MA ATS 2020 • Philadelphia, PA 120 TUESDAY • MAY 19